# Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

> **NCT04522544** · PHASE2 · RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 55 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable
- HCC

## Interventions

- **DRUG:** Tremelimumab
- **DRUG:** Durvalumab
- **PROCEDURE:** Y-90 SIRT
- **PROCEDURE:** DEB-TACE

## Key facts

- **NCT ID:** NCT04522544
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-15
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- AstraZeneca
- Hannover Medical School

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04522544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04522544, "Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04522544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*